MSB Provides Corporate Strategy For Neurologic Product
Filed with ASX · · 29 pages · English
Melbourne, Australia; 8 June 2012: Mesoblast Limited (ASX:MSB) today outlined the Company’s strategic plans to develop adult stem cell therapies for neurodegenerative diseases at the Jefferies Global Healthcare Conference in New York. In an update on Mesoblast’s strategic alliance with Teva Pharmaceutical Industries Ltd in the fields of neurologic and cardiovascular diseases, Chief Executive Profe
Earlier from Mesoblast
- Response to ASX price query
- Positive Disc Repair Results Using Mesoblast Stem Cells
- New Japanese Regenerative Medicine Legislation
- MSBs Registration Plans for GVHD Cell Product in Japan
- MSB Receives $4.3M Pipeline Funds from Australian Government
Later from Mesoblast
- Clearance for First Phase 2 Clinical Trial for Eye Diseases
- FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
- FDA Clearance for Phase 3 Bone Marrow Transplant Trial
- First European Trial for Heart Attack Treatment Cleared
- First Minimally Invasive Procedure for Lumbar Disc Repair
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast